As of 30 Sep 2025, 8 institutional investors reported holding $93,840,000 in principal (par value) of APELLIS PHARMACEUTICALS INC - NOTE 3.500% 9/1.
| Period | Principal | Value | Change | Price (% of par) (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q3 | $93,840,000 | $96,878,614 | +$573 | 102.94% | 8 |
| 2025 Q2 | $93,840,000 | $93,783,959 | -$35,700 | 99.67% | 8 |
| 2025 Q1 | $93,840,000 | $98,123,513 | -$3,660 | 104.45% | 9 |
| 2024 Q4 | $93,840,000 | $108,788,109 | -$12,068,348 | 115.78% | 9 |
| 2024 Q3 | $105,678,000 | $116,622,644 | -$335,580 | 109.6% | 9 |
| 2024 Q2 | $105,978,000 | $134,815,813 | +$14,469,718 | 127.96% | 9 |
| 2024 Q1 | $92,385,000 | $150,593,192 | +$20,888,181 | 163.14% | 13 |
| 2023 Q4 | $0 | $0 | -$7,451,400 | 102.94% | 0 |
| 2023 Q3 | $87,849,454 | $126,292,911 | -$48,933,368 | 125.62% | 11 |
| 2023 Q2 | $86,860,796 | $219,587,570 | -$13,926,028 | 239.58% | 14 |
| 2023 Q1 | $94,209,000 | $175,106,740 | +$774,017 | 185.97% | 9 |
| 2022 Q4 | $93,834,000 | $144,102,071 | -$5,747,612 | 153.61% | 11 |
| 2022 Q3 | $93,802,316 | $178,601,148 | -$79,412,063 | 194.55% | 12 |
| 2022 Q2 | $138,870,000 | $205,568,000 | -$92,786,573 | 149.3% | 12 |
| 2022 Q1 | $199,741,000 | $315,318,373 | +$5,808,493 | 158.3% | 16 |
| 2021 Q4 | $197,728,000 | $298,513,297 | +$5,674,200 | 151.23% | 22 |
| 2021 Q3 | $196,958,000 | $242,044,000 | -$336,407,635 | 122.79% | 22 |
| 2021 Q2 | $400,835,000 | $745,876,060 | +$577,341,623 | 185.94% | 37 |
| 2021 Q1 | $96,569,000 | $135,608,000 | -$99,945,335 | 140.39% | 20 |
| 2020 Q4 | $211,444,000 | $222,114,636 | -$60,381,047 | 167.78% | 28 |
| 2020 Q3 | $214,916,000 | $209,071,088 | +$209,070,345 | 107.39% | 26 |